Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03814902 · ClinicalTrials.gov registry record · NA
A Pilot Study to Characterize the Household Impact of Locating Devices for Children With ASD Who Wander
A NA study of Autism Spectrum Disorder and Wandering Behavior, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT03814902: Completed NA study of Autism Spectrum Disorder and Wandering Behavior, sponsored by Northwell Health.
NCT03814902 is a NA study of Autism Spectrum Disorder and Wandering Behavior that has completed, run by Northwell Health. The registered enrollment target is 31 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03814902, a NA study of Autism Spectrum Disorder and Wandering Behavior, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study will obtain preliminary data about the impact of wearable electronic tracking devices (ETDs) as an intervention for children with autism spectrum disorders (ASD) who wander. The feasibility of all study procedures and the acceptability of the intervention will be evaluated.
Primary Outcome
Participant retention will be assessed to evaluate the feasibility of all study procedures.
Conditions Studied
Interventions
- DEVICE Electronic Tracking Device
Study Locations (1)
New York
- Cohen Children's Medical Center of New York - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-11-11 |
| Phase | NA |
What the finished NCT03814902 record still lists
NCT03814902 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Electronic Tracking Device is the first listed.
NCT03814902 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03814902 about?
NCT03814902 is a clinical study titled "A Pilot Study to Characterize the Household Impact of Locating Devices for Children With ASD Who Wander". This pilot study will obtain preliminary data about the impact of wearable electronic tracking devices (ETDs) as an intervention for children with autism spectrum disorders (ASD) who wander. The feasibility of all study procedures and the acceptability of the intervention will be evaluated.
What is the current status of trial NCT03814902?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2019-01-15. Estimated completion is 2019-11-11.
What conditions does trial NCT03814902 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Wandering Behavior.
What interventions are being tested in trial NCT03814902?
The interventions under investigation include: Electronic Tracking Device (DEVICE).
Who is sponsoring clinical trial NCT03814902?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03814902 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03814902's enrollment target sits among peer trials
31 169th of 224 higher than 56 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Milieu Teaching-AV (MT-AV Pilot)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI